Eric J. Ende

Dr. Eric J. Ende has been a member of the Avadel Board of Directors since December of 2018. Eric currently serves as President of Ende BioMedical Consulting Group and as a member of Matinas BioPharma’s Board of Directors. Eric’s previous roles included serving on the Board of Progenics from 2019 until 2020 when it was acquired by Lantheus Holdings and serving on the Board of Directors of Genzyme from 2010 until it was acquired by Sanofi-Aventis in 2011 for $20 billion. During his tenure on Genzyme's Board of Directors, Eric was a member of the Audit and Risk Management Committees. Prior to acting as a Board Member for Genzyme, Dr. Ende acted as a biotechnology analyst, previously serving at Merrill Lynch, Bank of America Securities, and Lehman Brothers. Eric received undergraduate degrees from Emory University, his MD from the Icahn School of Medicine at Mount Saini, and an MBA from NYU Stern School of Business.